ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group Inc (SLS)

1.2199
0.0599
( 5.16% )
Updated: 15:14:13

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.2199
Bid
1.21
Ask
1.22
Volume
583,551
1.16 Day's Range 1.24
0.4986 52 Week Range 1.72
Market Cap
Previous Close
1.16
Open
1.17
Last Trade
1
@
1.215
Last Trade Time
15:14:20
Financial Volume
$ 702,107
VWAP
1.2032
Average Volume (3m)
519,934
Shares Outstanding
64,332,498
Dividend Yield
-
PE Ratio
-2.08
Earnings Per Share (EPS)
-0.58
Revenue
-
Net Profit
-37.34M

About SELLAS Life Sciences Group Inc

SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax. SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
SELLAS Life Sciences Group Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SLS. The last closing price for SELLAS Life Sciences was $1.16. Over the last year, SELLAS Life Sciences shares have traded in a share price range of $ 0.4986 to $ 1.72.

SELLAS Life Sciences currently has 64,332,498 shares outstanding. The market capitalization of SELLAS Life Sciences is $74.63 million. SELLAS Life Sciences has a price to earnings ratio (PE ratio) of -2.08.

SLS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.06996.078260869571.151.241.144556771.17223168CS
4-0.0201-1.620967741941.241.311.076236061.19366597CS
12-0.0901-6.877862595421.311.421.075199341.23739583CS
26-0.0701-5.434108527131.291.70.817470651.25993856CS
520.279929.77659574470.941.720.498610064981.12069835CS
156-8.0701-86.86867599579.299.620.49865149941.66701853CS
260-4.8301-79.83636363646.0519.380.49866928026.49120132CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
INODInnodata Inc
$ 42.0101
(72.60%)
8.42M
SEZLSezzle Inc
$ 426.29
(70.20%)
525.1k
PRCHPorch Group Inc
$ 3.7112
(59.28%)
15.17M
INDIindie Semiconductor Inc
$ 5.34
(55.69%)
32.04M
TIVCTivic Health Systems Inc
$ 0.3947
(51.52%)
283.72M
PRPHProPhase Labs Inc
$ 0.7701
(-46.15%)
2.36M
CHSNChanson International Holding
$ 5.53
(-39.03%)
486.79k
ALVRAlloVir Inc
$ 0.6034
(-38.52%)
1.84M
NXUNXU Inc
$ 0.3419
(-36.19%)
7.68M
ELWSEarlyworks Co Ltd
$ 4.32
(-36.00%)
661.19k
ELABElevai Labs Inc
$ 0.019
(6.15%)
400.32M
TIVCTivic Health Systems Inc
$ 0.3947
(51.52%)
283.72M
TSLATesla Inc
$ 321.5211
(8.29%)
170.32M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 19.105
(16.56%)
162.71M
WBUYWeBuy Global Ltd
$ 0.236599
(4.14%)
151.86M

SLS Discussion

View Posts
Boxsterfan Boxsterfan 1 week ago
How can you be investing in biotech companies and not know what an "open label phase 2" trial is?

Do you understand that the data from the SLS009 P2 trial is NOT blinded? They can peek at it every morning while eating their coffee and bagel. Even if it were goods news, it is immoral for the CEO to hold back the data from investors. It's not good news or Stergiou would be sharing it.
๐Ÿ‘๏ธ0
TTsr TTsr 1 week ago
Cheap FUD.  No company gives exact timlines when dealing with patients, the heterogeneity of cancer doesn't allow it.  The company stated 'expected' by 3rd qtr.
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 weeks ago
SLS009 updated data from Phase 2 is now 4 weeks overdue. The company specifically stated more data on SLS009 by end of Q3 2024.

More than likely, SLS009 has failed Phase 2.
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 3 weeks ago
Today's "fireside chat" happened for Sellas. What we re-learned:
1. Data for P3 REGAL trial is still imminent.
2. Data from SLS009 open label study is imminent.
3. RPDD with value of $0 for GPS. Pumping useless RPDD's is of no concern.
4. Everything is imminent and all is good.
5. Did I mention imminent? Because that has been the M.O. for the past year.
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 4 weeks ago
Huge news!! Sellas to have "fireside chat" at 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024 at 9:00 am EDT. This is incredible news!! These "fireside chats" are always filled with new information and probably has tons of info on their drug candidates never heard anywhere else before. LOLOLOLOLOLOLOLOLOLOLOLOLOL

https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Life-Sciences-to-Participate-in-Fireside-Chat-at-the-2024-Maxim-Healthcare-Virtual-Summit/default.aspx
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 months ago
I'm not giving you the valuable research that I did. One thing for sure is you know little about clinical trials.

Can the BAT change during a trial? Or must these CR2 patients in that arm just live (or rather die) with the old treatments from 2019? Would that be ethical? Would that be a test of BAT if it did?
๐Ÿ‘๏ธ0
TTsr TTsr 2 months ago
The Regal trial protocol was written in 2019โ€ฆ the five choices for BAT havenโ€™t changed, yes ven/aza combo is in BATโ€ฆ but lip services from leading clinicians in 2023 re: the same treatment options since ven/aza available since 2017-18โ€ฆ puhlease. Why donโ€™t you give me some FACTS like Iโ€™m doing for you? Explain your BAT 13 mOS with data!
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 months ago
Correct, my estimate. Those VIALE-A trials on CR1 patients were 3+ years ago. Other trials on CR2 patients were also years ago. The field has moved on since then and knows how to treat patients on ven/aza with additional inhibitors depending on the karyotypes presented. MRD negative status is also a huge helper in addition to patient age.

The doctors on the conference call last January were just giving lip service. Again, are you going to be able to sue them for saying "CR2 patients have a low 5-7 months expected survival"? If BAT MOS was 6 months, you would already have your 60 events. My last estimate has BAT 13 MOS vs GPS 21 MOS (0.619). It's very tight and the fact that Abbvie and Roche are seeing no degradation in stock price (and SLS seeing absolute nothing in stock price) indicates that it is not going to be a white Christmas.
๐Ÿ‘๏ธ0
TTsr TTsr 2 months ago
Your estimate!! So you see BAT living 13-14 mos?? Double of what the Drs conducting the trial, and the majority of CR2 trials produced? IA needs an HR on .52, and i bet they are close to that. P2 was 21 vs 5.5 mos and that was with a 12 injection schedule, not the 15 in Regal.
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 months ago
Correct. To pass muster at Final Analysis, they need to be 0.636. So at the last meeting, it is very tight. My estimates show it to be at 0.619.

So in June, at 0.619, you would not get a "halt for futility" or any "futility concerns". You would only get that if the HR number was above 0.636 and you still may not get a "futility halt" if the number was just slightly above 0.636 (say 0.643) at the time they looked at the data. You need to understand that the CEO (and company) is grifting investors.

Let's put it another way, when the trial fails, what "evidence" are you going to use to sue Stergiou and/or the company for lying about the trial? You won't have any because they have covered their bases.
๐Ÿ‘๏ธ0
TTsr TTsr 2 months ago
Is that what you took from the IDMCโ€™s last Regal update of โ€œNO CONCERNS REGARDING SAFETY OR FUTILITYโ€?
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 months ago
REGAL has failed means that the upcoming readout will be receiving a failing grade. They can't report until the 60th event, but at this point, it is obvious that this trial is DOA. Oncology is hard.
๐Ÿ‘๏ธ0
TTsr TTsr 2 months ago
If Regal โ€œhas failedโ€ it would be a material event and the company must inform the public with 3 trading days! You talk about โ€œpumpersโ€ and yet you state the trial has failed w/o a shred of evidence! That called FUD, but you already knew that, right?
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 2 months ago
Well, I used to think Sellas was going to be a stock to play. I used to think that it was going to have some decent volatility heading into September that would have nice to swing trade. But now, I will recognize that this stock is a sham. If you just go read the posts on other boards (like Stocktwits), it is like a desperation pump show. Ignore the posters over there like @GPS_vs_SOC and a few others that post all the time. Instead, watch the posters that do post with some regularity continually saying "they bought more shares" or "this is going to rocket soon" or etc, etc, etc...

In all likelihood, GPS REGAL trial has failed. Oncology is a tough business and it is even tough when the CEO is retarded.
๐Ÿ‘๏ธ0
Monksdream Monksdream 2 months ago
SLS under $2
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 3 months ago
Is it going to be a sh_t show for Sellas? Or a REG SHO extravagammasqueeze?
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
SLS under $2
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 4 months ago
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
SLS under $2
๐Ÿ‘๏ธ0
Boxsterfan Boxsterfan 4 months ago
https://duediligencegenie.com/wp-content/uploads/2024/05/Sellas-Life-Sciences.pdf This should be sticky posted.
👍️ 1
TTsr TTsr 5 months ago
The longer this goes, it is gonna POPโ€ฆ BP gotta know what SLS has, 2,assets that are extending OS 3 to 5X.
๐Ÿ‘๏ธ0
govprs govprs 5 months ago
https://www.barchart.com/stocks/quotes/SLS/opinion
๐Ÿ‘๏ธ0
peterus peterus 5 months ago
dilution turd
๐Ÿ‘๏ธ0
harry crumb harry crumb 6 months ago
Moneymaker here folks$$$$$
👍️ 1
TIMGZ TIMGZ 6 months ago
VERY OBSERVANT, THANK YOU FOR THE ANALOGY! TOMORROW MIGHT MAKE A DIFFERENCE****WE SHALL SEE
๐Ÿ‘๏ธ0
harry crumb harry crumb 6 months ago
Lol, oh there are still a stash of those, in the 20โ€™s! $$$$$!!
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
You should have taken CVNA which go to da moon
Now back to getting richer
๐Ÿ‘๏ธ0
harry crumb harry crumb 6 months ago
Huge move up could happen anytime, lottery play could go to da moon! $$$$$
๐Ÿ‘๏ธ0
TTsr TTsr 6 months ago
With positive REGAL results this will eventually explode
๐Ÿ‘๏ธ0
TTsr TTsr 6 months ago
According to the charters, which I am not, 9 million volume traded so far today - largest volume day in 3 years - 6 of the 9 million sold short
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
SLS under $2
๐Ÿ‘๏ธ0
TIMGZ TIMGZ 6 months ago
SURPRISED SLS IS NOT MOVING**** WAS AN EXCELLENT NEWS***** HOW ARE U *******

YOU ARE NOT AS FREQUENT AS BEFORE , YOU MUST BE SOMEWHERE ELSE***SHARE THE KNOWLEDGE
๐Ÿ‘๏ธ0
harry crumb harry crumb 6 months ago
Let er rip
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 6 months ago
1.27 SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level $SLS https://t.co/bQBsEQo7jc— Health Stocks News (@health_stocks) May 1, 2024
👍️ 1
harry crumb harry crumb 6 months ago
Somebody shorted the sh.. out of this today, pretty risky at this point, but whateverโ€ฆ.
๐Ÿ‘๏ธ0
govprs govprs 7 months ago
Yahoo finance add sls and review of the conversations tab.
๐Ÿ‘๏ธ0
peterus peterus 7 months ago
you have a link ?
๐Ÿ‘๏ธ0
govprs govprs 7 months ago
On yahoo they are talking 4 min.
๐Ÿ‘๏ธ0
harry crumb harry crumb 7 months ago
Agree, might see 1.70โ€™s again, worth the risk with a stop limit on shares purchased at 1$ or more
👍️ 1
peterus peterus 7 months ago
ok thanks
๐Ÿ‘๏ธ0
TTsr TTsr 7 months ago
I believe itโ€™s gonna before EOMโ€ฆ pr stated idmc scheduled โ€˜byโ€™ EOMโ€ฆ
๐Ÿ‘๏ธ0
peterus peterus 7 months ago
yup think next month data phase3 end april ... should see 1.50s before data
๐Ÿ‘๏ธ0
harry crumb harry crumb 7 months ago
Maybe another pop to 1.60
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
SLS 10Q due 3/22
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
SLS under $2
๐Ÿ‘๏ธ0
harry crumb harry crumb 8 months ago
Hit an run with this one
👍️ 1
harry crumb harry crumb 9 months ago
No way, lotto play here. This is nothing but risk
๐Ÿ‘๏ธ0
CarlCarlMcB CarlCarlMcB 10 months ago
Letโ€™s go $$$$$ reeling $$$$$$
๐Ÿ‘๏ธ0
harry crumb harry crumb 10 months ago
Junk
๐Ÿ‘๏ธ0
Monksdream Monksdream 10 months ago
SLS new 52 week low
๐Ÿ‘๏ธ0